BPC-157: Research Overview

Full name

Body Protection Compound-157 (Glycyl-L-glutamyl-L-prolyl-L-prolyl-L-prolyl-glycyl-L-lysyl-L-prolyl-L-alanyl-L-aspartyl-L-aspartyl-L-alanyl-glycyl-L-leucyl-L-valine)

Molecular formula

C62H98N16O22

Molecular weight

1419.55 g/mol

Sequence / class

15-residue linear pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)

Receptor targets

Reported interactions with VEGFR2 signaling, nitric oxide synthase pathways, and growth-hormone-receptor pathways in published in vitro literature

Research classification

Tissue signaling pentadecapeptide research reagent

PubChem CID

108101

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a protein originally identified in publicly available gastric tissue research. The molecule consists of fifteen amino-acid residues assembled in the linear sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular formula of C62H98N16O22 and a calculated monoisotopic mass near 1419 daltons. The compound carries no disulfide bridges or post-translational modifications, which simplifies its analytical characterization by reverse-phase HPLC and electrospray mass spectrometry.

Within publicly available literature, BPC-157 is classified as a tissue signaling research peptide. Published in vitro studies have examined the molecule in the context of angiogenic growth-factor cascades, with particular attention to VEGFR2 phosphorylation events and downstream MAPK pathway activation in cellular models. Additional reports describe interactions with nitric-oxide-synthase signaling and with growth-hormone-receptor expression in cultured fibroblast and endothelial systems.

Researchers in the published literature have used BPC-157 primarily as an analytical probe rather than as a therapeutic candidate. The compound is supplied to laboratory programs as a lyophilized powder for reconstitution in aqueous buffer or dilute acetic acid for in vitro assay use. Receptor-binding studies indicate that the peptide does not appear to engage a single canonical receptor in the classical sense; rather, the in vitro literature describes a pattern of pathway-level effects observed across multiple cellular model systems.

Published research suggests that the sequence is relatively resistant to enzymatic degradation in standard in vitro buffer conditions, a property that has made it useful as a reference compound for cellular signaling studies that require sustained exposure across multi-hour timecourses. This stability profile is one of the reasons the peptide has appeared frequently in published in vitro and animal-model methodology research.

Structure reference: Public domain chemical databases (PubChem CID 108101).

Published in vitro literature has examined BPC-157 in cellular signaling research contexts including endothelial tube-formation assays, fibroblast migration assays, and reporter cell systems engineered to read out MAPK and VEGFR2 cascade activity. Research published in international journals has described the peptide as a useful probe for investigating how synthetic peptide sequences modulate angiogenic signaling under controlled laboratory conditions.

Receptor-binding studies indicate that BPC-157 produces measurable changes in pathway-level readouts across several cellular model systems, including cultured endothelial cells, fibroblast lines, and tendon-derived cells used in published in vitro work. Investigators have used the compound in assays examining nitric-oxide signaling biochemistry, growth-hormone-receptor expression, and the kinetics of intracellular calcium response under defined buffer conditions.

The published literature also describes the use of BPC-157 as a comparator compound in cellular signaling research. Side-by-side comparison against vehicle controls and other peptide reagents in matched cellular models has been a common in vitro experimental design, allowing investigators to characterize the pathway-level signature of the compound under reproducible analytical conditions.

• [1]A study published in Journal of Physiology - Paris (2014) examined BPC-157 in the context of cellular signaling pathways and tissue research models, with discussion of pathway-level observations under in vitro conditions.
• [2]A study published in Current Pharmaceutical Design (2018) reviewed publicly available preclinical literature describing the analytical characterization and reported in vitro behavior of BPC-157 across multiple cellular research systems.
• [3]A study published in Molecular and Cellular Biochemistry (2010) investigated endothelial signaling responses to pentadecapeptide exposure in cultured cellular models.

The above represents a non-exhaustive summary of publicly available research. PūrTONIX does not endorse, validate, or make claims based on any referenced study.

Published chemical property data indicate that BPC-157 is freely soluble in water and dilute aqueous buffers. The lyophilized peptide is typically stored at -20°C under inert atmosphere to minimize oxidative degradation, and reconstituted stocks are best held in single-use aliquots to avoid repeated freeze-thaw cycles. Stability literature describes the peptide as relatively robust in neutral buffer at standard laboratory temperatures across the timecourses typical of in vitro signaling assays.

Reconstitution for in vitro assay use is commonly carried out in bacteriostatic water or in dilute aqueous buffer matched to the intended assay conditions. Reverse-phase HPLC purity analysis, combined with electrospray mass spectrometry for identity confirmation, are analytical methods commonly used to characterize research-grade peptides.

Handling recommendations are based on published chemical property data and are intended for qualified laboratory personnel only.

Reproducible in vitro work with BPC-157 depends on well-characterized material with high chromatographic purity. Below that level, deletion peptides and truncation byproducts from solid-phase synthesis can confound pathway-level readouts in sensitive cellular signaling assays. Analytical documentation for research-grade material typically covers chromatographic purity, mass-spectral identity, and residual solvent screening.